Altimmune diskutieren
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $20.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $50.00 to $15.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $15.00 to $8.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at HC Wainwright from $15.00 to $12.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $25.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Neueste Beiträge
Jefferies_Financial_ in Baidu Inc. A ADR diskutieren